University Hospitals (UH) Seidman Cancer Center in Ohio, US, has joined the Caris Precision Oncology Alliance (POA), a network of cancer centres and research consortia that collaborate to advance precision oncology and biomarker-driven research.
The alliance allows its members to leverage Caris’ clinico-genomic database, with an aim to help boost cancer patients’ clinical outcomes.
It comprises 87 cancer centres, academic institutions, research consortia and healthcare systems.
UH Seidman Cancer Center president and scientific director Theodoros Teknos said: “The collective power wrought by combining artificial intelligence (AI) with the brightest oncologic minds and the most extensive cancer profiling database is sure to lead to breakthroughs in cancer care.
“The academic faculty at University Hospitals Seidman Cancer Center are thrilled to join forces with the Caris Precision Oncology Alliance.
“This collaborative effort solidifies our reputation as one of the leading cancer research institutions in the world.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataUH Seidman is claimed to be the only freestanding cancer hospital in Northeast Ohio and is part of the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center at Case Western Reserve University.
The addition of UH Seidman to the alliance is considered a significant step forward in the fight against cancer.
POA chairman Chadi Nabhan said: “The researchers, clinicians, and leaders of Seidman Cancer Center share the same vision of the Caris Precision Oncology Alliance, to improve the outcomes of all patients diagnosed with cancer through cutting-edge precision oncology research.”